Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

Blood Cancer Journal

Volumn 5, Issue 8, 2015, Pages

  Barbui, T ^a   Thiele, J ^b   Vannucchi, A M ^c   Tefferi, A ^d  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALR PROTEIN; ERYTHROPOIETIN; HEMOGLOBIN; JANUS KINASE 2; MPL PROTEIN; PROTEIN; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN;

ALLELE; CLONAL VARIATION; GENE MUTATION; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; REVIEW; SOMATIC MUTATION; THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION; BONE MARROW; FEMALE; GENETICS; MALE; MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

BONE MARROW; FEMALE; HUMANS; JANUS KINASE 2; MALE; MUTATION; POLYCYTHEMIA VERA; PRACTICE GUIDELINES AS TOPIC; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; WORLD HEALTH ORGANIZATION;

EID: 84975286202     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.64     Document Type: Review

References (100)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001.
2. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al.. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008.
5. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179-3184.
6. Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117: 5710-5718.
7. Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012; 7: e35631.
8. Ejerblad E, Kvasnicka HM, Thiele J, Andreasson B, Björkholm M, Löfvenberg E et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology 2013; 18: 8-13.
9. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121: 1720-1728.
10. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al. Survival and prognosis among 1,545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27: 1874-1881.
11. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 915-925.
12. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008; 112: 231-239.
13. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M et al. Guidelines for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352-375.
14. Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR et al. Modification of British Committee for Standards in Haematology criteria for essential thrombocythaemia. Br J Haematol 2014; 167: 421-423.
15. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013; 27: 1953-1958.
16. Alvarez-Larran A, Ancochea A, Gracia M, Climent F, Gracia-Pallarols F, Angona A et al. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol 2014; 166: 911-919.
17. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
18. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl JMed 2013; 369: 2391-2405.
19. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al. Long-term survival and blast transformation between molecularly-annotated essential thrombocythemia, polycythemia vera and primary myelofibrosis. Blood 2014; 124: 2507-2513.
20. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
21. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
22. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207-1209.
23. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
24. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960-1963.
25. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005; 131: 166-171.
26. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs Jr KD et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
27. Broseus J, Park JH, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014; 124: 3964-3966.
28. Tefferi A, Thiele J, Vardiman J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; 28: 1407-1413.
29. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
30. Pardanani A, Lasho TL, Finke CM, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol 2011; 86: 701-702.
31. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
32. Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J et al. JAK2 (V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009; 37: 1186-1193.
33. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761.
34. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114: 1477-1483.
35. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574-1579.
36. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631-635.
37. Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 2014; 124: 2611-2612.
38. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL et al. Type1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014; 89: 121-124.
39. Tefferi A, Lasho TL, Tischer A, Wassie EA, Finke CM, Belachew AA et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014; 124: 2465-2466.
40. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
41. Tefferi A, Finke CM, Lasho TL, Wassie EA, Knudson R, Ketterling RP et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2014; 28: 431-433.
42. Laborde RR, Patnaik MM, Lasho TL, Finke CM, Hanson CA, Knudson RA et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia 2013; 27: 2100-2102.
43. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487.
44. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498.
45. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478.
46. Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28: 1804-1810.
47. Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice combine to promote disease progression in myeloproliferative neoplasms. Blood 2015; 125: 327-335.
48. Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014; 111: 5401-5410.
49. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 2015; 372: 601-661.
50. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-4290.
51. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B et al. Guidelines for the diagnosis, investigation and management of polycythemia/ erythrocytosis. Br J Haematol 2005; 130: 174-195.
52. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005; 129: 701-705.
53. Tefferi A. The rise and fall of red cell mass measurement in polycythemia vera. Curr Hematol Rep 2005; 4: 213-217.
54. Cassinat B, Laguillier C, Gardin C, de Beco V, Burcheri S, Fenaux P et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for the red cell mass? Leukemia 2008; 22: 352-453.
55. Alvarez-Larrán A, Ancochea A, Angona A, Pedro C, García-Pallarols F, Martínez-Avilés L et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 2012; 97: 1704-1707.
56. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013; 122: 1881-1886.
57. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2014; 89: 52-54.
58. Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014; 89: 199-202.
59. Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol. 2014; 89: 588-590.
60. Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Leukemia 2014; 28: 2092-2094.
61. Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythemia vera. Br J Haematol 2014; 167: 541-546.
62. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005; 20: 317-328.
63. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005; 113: 213-219.
64. Gianelli U, Iurlo A, Vener C, Moro A, Fermo E, Bianchi P et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the early prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008; 130: 336-342.
65. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010; 85: 62-66.
66. Gianelli U, Bossi A, Cortinovis I, Sabattini E, Tripodo C, Boveri E et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol 2014; 27: 814-822.
67. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132.
68. Ellis JT, Peterson P. The bone marrow in polycythemia vera. Pathol Ann 1979; 1: 383-403.
69. Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A et al. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience. Am J Hematol 2013; 88: 1012-1016.
70. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features - a clinicopathological study on 272 patients. Histol Histopathol 2003; 18: 93-102.
71. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009; 4: 33-40.
72. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004; 89: 911-919.
73. Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006; 47: 1774-1781.
74. Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol 2014; 27: 1447-1454.
75. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993; 189: 121-132.
76. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996; 22: 15-29.
77. Kreft A, Büche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 2005; 113: 137-143.
78. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012; 119: 2239-2241.
79. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986; 23: 144-155.
80. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
81. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56: 168-172.
82. Lengfelder E, Hochhaus A, Kronawitter U, Höche D, Queisser W, Jahn-Eder M et al. Should a platelet limit of 6006109/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998; 100: 15-23.
83. Sacchi S, Vinci G, Gugliotta L, Rupoli S, Gargantini L, Martinelli V et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 6006109/l. Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC). Haematologica 2000; 85: 492-495.
84. Tefferi A, Hanson CA. Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc 2005; 80: 923-936.
85. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 1999; 245: 295-300.
86. Schafer AI. Thrombocytosis. N Engl J Med 2004; 350: 1211-1219.
87. Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013; 98: 1872-1876.
88. Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010; 56: 758-767.
89. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009; 27: 2991-2999.
90. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005; 20: 633-644.
91. Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van Der Walt J, Kreipe HH. European Bone Marrow Working Group trial on reproducibility of WHO criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012; 97: 360-365.
92. Koopmans SM, Bot FJ, Lam KH, van Marion AM, de Raeve H, Hebeda KM. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am J Clin Pathol 2011; 136: 618-624.
93. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954-2970.
94. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 2006; 32: 362-371.
95. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 2006; 85: 226-232.
96. Buhr T, Büsche G, Choritz H, Länger F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003; 119: 152-158.
97. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003; 44: 949-953.
98. Barosi G. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol 2014; 27: 129-140.
99. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26: 716-719.
100. Pozdnyakova O, Rodig S, Bhandarkar S, Wu K, Thiele J, Hasserjian R. The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading. Leukemia 2015; 29: 241-244.